Methisine

Inosine Pranobex

Method of action: Immunomodulating, Immunostimulants

Treatment option: Varicella-Zoster, Genital Herpes, Cold Sore, Herpetic Keratitis, Influenza, Infectious Mononucleosis, Infection, Keratitis, Molluscum Contagiosum, Measles

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Methisine

Quick Facts

Property	Description
Active Ingredient	Inosine Pranobex
Form	Tablets, Oral Solution
Pharmacological Class	Immunomodulator, Antiviral Agent
General Purpose	Supports cell-mediated immunity
Origin	Synthetic compound

Methisine: What Kind of Drug is Inosine Pranobex?

Methisine is a prescription pharmaceutical product primarily identified by its active ingredient, Inosine Pranobex, a synthetic compound that functions with a dual role as an immunomodulator and a systemic antiviral agent. This classification places it within the Anatomical Therapeutic Chemical (ATC) system under the code J05AX05, which designates it among Other Antivirals. Pharmacological studies and research reviews have clinically recognized the drug's established immunomodulatory capacity. The medication, sometimes known by its synonyms such as Methisoprinol or Inosiplex, is a purine derivative engineered to modulate and support the body's defensive response, particularly in contexts involving typical viral challenges.

Composition and Form: The Structure of Methisine

The core of Methisine lies in its active substance, Inosine Pranobex, which is a precise complex-based combination product composed of three molecular components. This unique chemical structure is an alkylamino-alcohol complex uniting the purine nucleoside Inosine with the salt Dimepranol Acedoben in a specific molar ratio. This combination architecture is a key differentiating feature. Methisine is prepared for oral administration, typically provided to patients in the convenient dosage forms of tablets and an oral solution, with the solution often preferred for ease of use in pediatric or elderly patients.

General Purpose: How Methisine Supports the Body's Defenses

The general purpose of Methisine is to reinforce the body's defenses by acting as an immunostimulant that targets cell-mediated immune processes. It works by promoting the maturation and differentiation of specialized white blood cells known as T-lymphocytes. By facilitating a stronger, more coordinated immune response, the drug aims to enhance the body's inherent ability to respond effectively to challenges requiring robust immune system involvement.

What side effects are possible with Methisine?

Possible Side Effects and Safety Information

The safety profile of Methisine (Inosine Pranobex) is defined by officially documented adverse reactions classified by frequency and the body system affected, as stated in regulatory documents.

Frequency-Classified Adverse Reactions

The most consistently observed finding is classified as Very Common in regulatory documents: a transient elevation of uric acid levels in both the blood and urine. These levels are expected to return to baseline shortly after the medicine is discontinued.

Common reactions reported across different system classes include:

System Organ Class	Common Adverse Reaction
Nervous system	Headache, Vertigo
Gastrointestinal	Nausea, Vomiting, Epigastric discomfort/pain
General Disorders	Fatigue, Malaise

Uncommon reactions may include nervousness, insomnia, somnolence, diarrhea, constipation, and increased urination (polyuria).

Serious Reactions and Constraints

The regulatory profile documents the potential for serious acute hypersensitivity reactions, including anaphylactic reaction/shock, angioedema, and urticaria (hives). These are classified with a frequency of Not Known.

Safety constraints and situations requiring caution are also outlined. The medicine is formally contra-indicated in individuals with a known hypersensitivity to the drug, or those with acute gout or pre-existing elevated blood uric acid levels.

For long-term treatment (defined as three months or longer), regulatory documents state that regular monitoring of uric acid levels, liver function, renal function, and blood count is necessary. Caution is also advised for patients with a history of urolithiasis or impaired renal function.

Overdose and Emergency Response

Overdose and when to seek help

Methisine (Methadone) overdose is a life-threatening medical emergency. The classic signs of acute, severe overdose, which may be fatal, are profound respiratory depression (slowed or shallow breathing), extreme somnolence progressing to stupor or coma, and pinpoint pupils (miosis). Cardiac complications, specifically QT interval prolongation and serious arrhythmia, are also documented risks in overdose situations.

Accidental ingestion by children is extremely dangerous and has resulted in death. The risk of overdose is significantly increased by the concomitant use of other Central Nervous System (CNS) depressants, including alcohol, or by drugs that inhibit certain liver enzymes (CYP450 isoenzymes), which can cause Methisine levels to accumulate to toxic amounts.

When to Seek Immediate Medical Help

Seek emergency medical help or call 911 immediately if any individual exhibits signs of respiratory difficulty, severe sleepiness, confusion, inability to wake up, or any suspected overdose symptoms. The management of overdose requires establishing a patent airway and providing assisted ventilation. An opioid antagonist (e.g., naloxone) should be administered as an antidote, although repeated doses are often necessary because Methisine's effects persist longer than the antagonist's action. Supportive measures, including oxygen and vasopressors, are also required for treating circulatory shock.

Therapeutic Uses of Methisine

What Methisine Treats: Main Uses and Benefits

Methisine (Inosine Pranobex) is a supportive medication relevant in clinical settings that involve acute or unstable symptom patterns where additional symptomatic support is needed. It is considered relevant for easing symptoms across several key therapeutic domains.

The medication is applied in addressing conditions that present with acute or recurrent episodes, including systemic viral illnesses such as influenza and herpesvirus infections, like cold sores and genital lesions. It is relevant for genital warts where it may be part of symptomatic management, and in the rare, severe complication Subacute Sclerosing Panencephalitis (SSPE).

Its therapeutic goal is focused on providing relief in these symptomatic presentations. The primary patient benefit is that it provides support that helps ease the overall symptom burden of the illness, assisting individuals in coping more steadily with difficult episodes and may assist with maintaining a sense of stability when symptoms are more noticeable.

“This medication is relevant when supportive symptom management is appropriate and symptoms become more disruptive during flare-ups.”

Quick Fact: Relief for Acute and Recurrent Symptoms

Focus Area	Symptom Domain	Patient Benefit
Acute Viral	Fever, malaise, fatigue	Supports easing the overall symptom load
Recurrent Lesions	Symptoms that become more disruptive during flare-ups	May assist with managing frequency of manifestations
Complex Challenges	Persistent viral activity	Contributes to maintaining functional stability

Eligibility and Restrictions for Use

Methisine (Inosine Pranobex) use is strictly governed by regulatory documentation detailing specific eligibility and non-eligibility requirements.

Absolute Contraindications

Methisine is contraindicated and must not be used in patients with known hypersensitivity to the active substance or its excipients. It is also contraindicated in patients with established gout or those who present with high serum uric acid levels, due to the drug’s metabolic pathway.

Conditional Use and Restrictions

The medicine is generally permitted for use in adult and pediatric populations for labeled indications. However, caution is advised for patients with a history of hyperuricaemia (elevated uric acid), urolithiasis (kidney stones), or impaired renal function. For the aging population, caution is also formally noted regarding the drug’s effect on uric acid. Long-term treatment mandates regular monitoring of kidney and uric acid status.

Reproductive Status

Methisine is not recommended during pregnancy or lactation. It should only be administered if the prescribing physician determines that the potential benefits formally and explicitly outweigh the potential risks, as excretion into human milk is not known.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Methisine (Inosine Pranobex) is officially documented by regulatory agencies and is primarily structured around metabolic processes and effects on co-administered agents. The drug’s catabolism causes a transient elevation of serum and urinary uric acid levels, which is the basis for a pharmacodynamic interaction.

Interactions Affecting Uric Acid

Due to the documented effect on uric acid, caution is required when Methisine is co-administered with Xanthine Oxidase Inhibitors, such as allopurinol, or with Uricosuric Agents and specific Diuretics like furosemide and hydrochlorothiazide.

Patients with pre-existing conditions such as gout, hyperuricaemia, or impaired renal function require specific caution, as the clinical relevance of these interactions is heightened by the drug’s inherent effect on uric acid homeostasis.

Mechanism of Action

Methisine, an essential amino acid, functions by intervening in core intracellular metabolic pathways that govern cellular homeostasis and physiological balance.

Modulation of Transmethylation Pathways

Methisine acts as a direct precursor to S-adenosylmethionine (SAMe), the primary universal methyl donor. This interaction initiates signaling sequences required for the transfer of methyl groups to DNA, proteins, and phospholipids. This methylation process modulates gene expression and affects the overall state of regulation within targeted metabolic pathways.

Influence on Antioxidant Defense Systems

The molecule modifies early molecular steps within the transsulfuration pathway. This cascade yields cysteine, which is subsequently used for the intracellular synthesis of the tripeptide glutathione. The resultant increase in glutathione availability contributes to regulating physiological responses by influencing the intracellular oxidation-reduction (redox) status and the effect profile of specific biological mediators.

Dosage and Administration Information

Instruction Map: How to use Methisine — Administration Guidelines

Administration scope

Feature	Guideline
Route of administration	Oral administration only.
Dosing schedule	The recommended dosage is 50 mg per kg of body weight per day for adults and children. The total dose is usually 3 g/day, up to a maximum of 4 g/day.
Timing in relation to meals	May be taken with or without food.
Preparation requirements	The 500 mg tablets may be crushed and dissolved in a small amount of flavored liquid to assist with ingestion.
Age-group administration rules	The standard weight-based dosage applies to both Adults and Children, including the elderly.
Missed-dose rules	If a dose is missed, it should be taken when remembered, but skipped if it is close to the time of the next scheduled dose.
Special procedural conditions	The score-line on the tablet is designed only to facilitate breaking for ease of swallowing, not for dividing the tablet into equal doses.

Instruction classifications (high-level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Daily, administered in 3 to 4 equally divided doses during waking hours.
Basis of application	Based on standardized prescribing protocols and pharmaceutical guidelines.
Use-context constraints	Usage is typically time-bound, such as a course of 10 days for acute viral presentations, or extended treatment for specific conditions like Subacute Sclerosing Panencephalitis (SSPE).

Resulting procedural structure

Step sequence:

Determine the total daily dose based on the 50 mg/kg/day principle, not exceeding the maximum daily limit.
Divide the total daily dose into 3 to 4 equal portions.
Administer these portions orally, with or without food, throughout the waking hours.

Connection to the overall use protocol: The instructions establish a structured, weight-based approach to medication use, defining the oral route, the daily dosage calculation, and the required divided schedule to ensure consistent administration. These requirements formalize the procedural steps for taking the medicine, making the use pattern standardized across populations.

Recent Clinical Evidence

Methisine: Overview of Studies and Research Gaps

Evidence for Use in Acute Viral Illnesses

Research has examined Methisine (Inosine Pranobex) in acute viral respiratory infections, such as influenza-like illness. Studies for this indication primarily use Randomized, Placebo-Controlled Trials (RCTs) exploring outcomes related to physical discomfort, specifically the time needed for all acute symptoms—like fever and fatigue—to fully resolve. In the full group of patients evaluated, the measured changes in the primary endpoint were sometimes not significantly distinct from the control group receiving a placebo. Follow-up durations were limited to the acute phase of the illness.

Evidence for Use in Recurrent Herpesvirus Infections

Methisine was also studied for recurrent herpesvirus infections, specifically cold sores (herpes labialis) and genital lesions (herpes genitalis). The research relies on controlled trials that monitored specific outcomes describing episodic changes. Researchers examined measured short-term recurrence rates over defined time intervals. Evidence is limited regarding the durability of the observed short-term outcomes over extended periods.

Evidence for Persistent Viral Challenges

Research for persistent viral challenges, like genital warts (HPV), often explored the drug’s use in combination with conventional therapies (as an adjuvant approach). Findings regarding lesion resolution were not uniform when compared to placebo alone. For Subacute Sclerosing Panencephalitis (SSPE), non-randomized studies monitored neurological function and long-term survival rates. Certainty remains low for SSPE due to the reliance on non-randomized data and its use in multi-drug treatment plans.

Research Gaps and Areas of Uncertainty

The research on Methisine has several documented limitations. Comparative evidence is lacking for the drug used as a single treatment (monotherapy) for genital warts. Findings were not uniform across subgroups in the viral illness studies, meaning results apply primarily to the specific populations studied and do not generalize broadly without further data.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Methisine (FAQ)

Q: What is Methisine used for?

A: Methisine is indicated for the management of chronic, non-malignant pain in adults who have not responded adequately to other treatments. The precise uses are defined by the product's official prescribing information.

Q: How quickly does Methisine start working?

A: The time it takes for an individual to observe an effect from Methisine may vary. Clinical data suggests that initial effects might be observed after several weeks of consistent use, but it is important to follow the guidance of a healthcare professional regarding the expected timeline for therapeutic response.

Q: Can Methisine be stopped suddenly?

A: Suddenly stopping Methisine is generally not recommended. Abrupt discontinuation may be associated with certain discomforts or withdrawal effects. If a change in treatment is necessary, a healthcare provider should be consulted to develop a schedule for gradual dose reduction.

Q: What should I do if I miss a dose?

A: Specific instructions for missed doses are included in the official labeling for Methisine. In general, it is often advised to take the missed dose as soon as it is remembered unless it is nearly time for the next scheduled dose. Never take two doses at the same time to make up for a missed dose. A healthcare provider can offer the most accurate instruction based on the individual's treatment plan.

Q: Does Methisine interact with other medications?

A: Methisine may interact with various other substances, including certain prescription drugs, over-the-counter products, and herbal supplements. These interactions can potentially alter the drug's effects or increase the risk of side effects. It is essential to provide a complete list of all current medications to a healthcare professional or pharmacist to review potential interactions.

How should Methisine be stored and disposed of?

How to Store and Dispose of Methisine

Methisine (Inosine Pranobex) must be stored and disposed of according to official regulatory labeling to maintain stability.

Storage Conditions

Both the tablets and oral solution must be stored below 25 C. The tablets require protection from moisture and should be kept in the original package. For the oral solution, stability rules mandate that it must be used within 6 months after the initial opening, maintaining the 25 C temperature limit. The medicine must always be stored out of the sight and reach of children.

Disposal Instructions

Official disposal rules prohibit throwing unused or expired Methisine into wastewater or household waste. For proper disposal, individuals should ask their pharmacist how to throw away medicines they no longer use, ensuring compliance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.